StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.91−0.29 (-9.06%)

Close on Nov 19, 2026Market cap $264.77MP/E –Yield –

SAB Biotherapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for SAB Biotherapeutics

SAB Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More SAB Biotherapeutics figures

See a number that looks wrong?